DK2705143T3 - Protein-induceret pluripotent celleteknologi og anvendelse deraf - Google Patents
Protein-induceret pluripotent celleteknologi og anvendelse deraf Download PDFInfo
- Publication number
- DK2705143T3 DK2705143T3 DK12779306.5T DK12779306T DK2705143T3 DK 2705143 T3 DK2705143 T3 DK 2705143T3 DK 12779306 T DK12779306 T DK 12779306T DK 2705143 T3 DK2705143 T3 DK 2705143T3
- Authority
- DK
- Denmark
- Prior art keywords
- protein
- induced pluripotent
- pluripotent cell
- cell technology
- technology
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5073—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/602—Sox-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/603—Oct-3/4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/604—Klf-4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/605—Nanog
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/606—Transcription factors c-Myc
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1307—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from adult fibroblasts
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Developmental Biology & Embryology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- General Engineering & Computer Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161481273P | 2011-05-02 | 2011-05-02 | |
| PCT/US2012/036051 WO2012151234A2 (en) | 2011-05-02 | 2012-05-02 | A protein-induced pluripotent cell technology uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2705143T3 true DK2705143T3 (da) | 2021-05-10 |
Family
ID=47108197
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12779306.5T DK2705143T3 (da) | 2011-05-02 | 2012-05-02 | Protein-induceret pluripotent celleteknologi og anvendelse deraf |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US9816076B2 (da) |
| EP (2) | EP3777538B1 (da) |
| CN (2) | CN107012118A (da) |
| DK (1) | DK2705143T3 (da) |
| ES (2) | ES2957478T3 (da) |
| PL (1) | PL2705143T3 (da) |
| PT (1) | PT2705143T (da) |
| WO (1) | WO2012151234A2 (da) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| CA2821992A1 (en) | 2010-10-01 | 2012-04-05 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| ES2957478T3 (es) | 2011-05-02 | 2024-01-19 | Univ Wayne State | Una tecnología de células madre pluripotentes inducidas por proteínas y usos de las mismas |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| SG11201401196WA (en) | 2011-10-03 | 2014-05-29 | Moderna Therapeutics Inc | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| SG10201604896TA (en) | 2011-12-16 | 2016-08-30 | Moderna Therapeutics Inc | Modified nucleoside, nucleotide, and nucleic acid compositions |
| US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| WO2013151670A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| EP4074834A1 (en) | 2012-11-26 | 2022-10-19 | ModernaTX, Inc. | Terminally modified rna |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| WO2015051214A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| WO2015061779A1 (en) * | 2013-10-25 | 2015-04-30 | Wayne State University | Methods, systems and compositions relating to cell conversion via protein induced in-vivo cell reprogramming |
| KR101781693B1 (ko) * | 2015-09-24 | 2017-09-26 | 서울대학교병원 | 심장내막 유래 성체줄기세포로부터 제조된 유도만능 줄기세포의 심혈관계 세포로의 분화방법 및 이의 용도 |
| GB201909975D0 (en) * | 2019-07-11 | 2019-08-28 | Babraham Inst | Novel reprogramming method |
| WO2021149823A1 (ja) * | 2020-01-24 | 2021-07-29 | アイ ピース， インコーポレイテッド | 因子を導入された細胞の培養方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US7943300B2 (en) | 2001-07-06 | 2011-05-17 | Merck Patent Gmbh | Method for improved protein expression in bacteria by monitoring and modulating protein folding |
| PT1448772E (pt) | 2001-11-30 | 2007-10-02 | Serono Lab | Método para aumentar os níveis de expressão do receptor de tnf humano |
| US20030134352A1 (en) | 2002-01-04 | 2003-07-17 | Freimuth Paul I. | Facilitating protein folding and solubility by use of peptide extensions |
| AU2003201727A1 (en) | 2002-01-07 | 2003-07-24 | European Molecular Biology Laboratory | Recombinant protein expression |
| WO2005026196A2 (en) | 2003-09-12 | 2005-03-24 | Novexin Limited | Methods for folding proteins and reducing protein aggregation |
| SG10201808863UA (en) * | 2008-03-17 | 2018-11-29 | Scripps Research Inst | Combined chemical and genetic approaches for generation of induced pluripotent stem cells |
| US8722348B2 (en) * | 2008-05-28 | 2014-05-13 | Wayne State University | Method and composition for a protein transduction technology and its applications |
| US8530238B2 (en) | 2008-06-27 | 2013-09-10 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
| EP2414510A4 (en) * | 2009-04-03 | 2013-04-17 | Mclean Hospital Corp | INDUCED PLURIPOTENT STEM CELLS |
| WO2010124143A1 (en) * | 2009-04-23 | 2010-10-28 | Nevada Cancer Institute | Reprogramming of somatic cells with purified proteins |
| EP2253700A1 (en) * | 2009-05-13 | 2010-11-24 | Helmholtz-Zentrum für Infektionsforschung GmbH | A method for producing test systems from donors suffering from adverse effects of medicaments and /or medical treatments, and uses of said systems |
| CN101993495B (zh) * | 2009-08-12 | 2013-07-24 | 上海近岸科技有限公司 | 一种蛋白质混合物及其制备方法 |
| JP2013510563A (ja) * | 2009-11-13 | 2013-03-28 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 操作された微小胞を用いた真核細胞のリプログラミング |
| CN101906419A (zh) * | 2010-07-29 | 2010-12-08 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 可用于高效制备诱导性多能干细胞的小分子化合物和方法 |
| ES2957478T3 (es) * | 2011-05-02 | 2024-01-19 | Univ Wayne State | Una tecnología de células madre pluripotentes inducidas por proteínas y usos de las mismas |
-
2012
- 2012-05-02 ES ES20197841T patent/ES2957478T3/es active Active
- 2012-05-02 DK DK12779306.5T patent/DK2705143T3/da active
- 2012-05-02 CN CN201710255470.6A patent/CN107012118A/zh active Pending
- 2012-05-02 WO PCT/US2012/036051 patent/WO2012151234A2/en active Application Filing
- 2012-05-02 US US14/113,522 patent/US9816076B2/en active Active
- 2012-05-02 EP EP20197841.8A patent/EP3777538B1/en active Active
- 2012-05-02 CN CN201280032517.8A patent/CN103826459B/zh active Active
- 2012-05-02 PL PL12779306T patent/PL2705143T3/pl unknown
- 2012-05-02 PT PT127793065T patent/PT2705143T/pt unknown
- 2012-05-02 EP EP12779306.5A patent/EP2705143B1/en active Active
- 2012-05-02 ES ES12779306T patent/ES2866411T3/es active Active
-
2017
- 2017-11-09 US US15/808,205 patent/US10221397B2/en active Active
-
2019
- 2019-02-08 US US16/271,150 patent/US10640751B2/en active Active
-
2020
- 2020-04-15 US US16/849,515 patent/US11685903B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012151234A3 (en) | 2014-02-20 |
| ES2957478T3 (es) | 2024-01-19 |
| US10640751B2 (en) | 2020-05-05 |
| CN107012118A (zh) | 2017-08-04 |
| PT2705143T (pt) | 2021-04-07 |
| US20140242695A1 (en) | 2014-08-28 |
| ES2866411T3 (es) | 2021-10-19 |
| EP3777538A1 (en) | 2021-02-17 |
| EP2705143A4 (en) | 2015-12-16 |
| US9816076B2 (en) | 2017-11-14 |
| EP3777538B1 (en) | 2023-06-28 |
| US20190161739A1 (en) | 2019-05-30 |
| WO2012151234A2 (en) | 2012-11-08 |
| EP2705143B1 (en) | 2021-02-17 |
| US20200291362A1 (en) | 2020-09-17 |
| CN103826459B (zh) | 2017-05-10 |
| US11685903B2 (en) | 2023-06-27 |
| EP2705143A2 (en) | 2014-03-12 |
| CN103826459A (zh) | 2014-05-28 |
| US20180127725A1 (en) | 2018-05-10 |
| PL2705143T3 (pl) | 2021-07-19 |
| US10221397B2 (en) | 2019-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2705143T3 (da) | Protein-induceret pluripotent celleteknologi og anvendelse deraf | |
| DK2855736T3 (da) | Elektrolysator og energisystem | |
| DK3346008T3 (da) | Rekombinante mikroorganismer og anvendelser deraf | |
| CO7030961A2 (es) | Benzotienilo-pirrolotriazinas disustituidas y sus usos | |
| SMT201500055B (it) | Dispositivi e metodi per la coltura di cellule | |
| DK3354665T3 (da) | Modificerede alginater til celleindkapsling og celleterapi | |
| EP2811011A4 (en) | CELL CULTURE KIT AND METHOD FOR USING THE CELL CULTURE KIT | |
| DK2850202T3 (da) | Fremgangsmåder og grupper | |
| DK2837680T3 (da) | Mammaliacellekultur | |
| DK3404027T3 (da) | Cellekernetransportmodulatorer og anvendelser deraf | |
| DK3045187T3 (da) | Injektor og fremgangsmåde til samling | |
| DK3351620T3 (da) | Metabolsk optimeret cellekultur | |
| DK3257943T3 (da) | Fremgangsmåder og vektorer til celleimmortalisering | |
| DK3401319T3 (da) | Celledyrkningsmedium | |
| SG2014013676A (en) | Therapeutics using adipose cells and cell secretions | |
| CO6870031A2 (es) | Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos | |
| DK2785683T3 (da) | Inkt-cellemodulatorer og fremgangsmåder til anvendelse heraf | |
| DK3326642T3 (da) | Langtidsvirkende koagulationsfaktorer og brugen deraf | |
| HK1214412A1 (zh) | 電化學生物反應器模塊和使用所述模塊的方法 | |
| DK3567099T3 (da) | Nyrecellepopulationer og anvendelser deraf | |
| DK2600715T3 (da) | Flydende ST-246-formuleringer og fremgangsmåder | |
| HK1214292A1 (zh) | 灌注培養方法及其用途 | |
| DK2795177T3 (da) | Flydende metan-lagringssystem og fremgangsmåde | |
| DK2704744T3 (da) | Komplementfaktor-b-analoger og anvendelser deraf | |
| DK2753346T3 (da) | Ceramidase og celledifferentiering |